Yaman, S. Et Al. 2022. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia , vol.22, no.2 .

Yaman, S., Başcı, S., Turan, G., Ulu, B. U., Yiğenoğlu, T. N., Dal, M. S., ... Kızıl Çakar, M.(2022). Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia , vol.22, no.2.

Yaman, Samet Et Al. "Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies," Clinical Lymphoma, Myeloma and Leukemia , vol.22, no.2, 2022

Yaman, Samet Et Al. "Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies." Clinical Lymphoma, Myeloma and Leukemia , vol.22, no.2, 2022

Yaman, S. Et Al. (2022) . "Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies." Clinical Lymphoma, Myeloma and Leukemia , vol.22, no.2.

@article{article, author={Samet Yaman Et Al. }, title={Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies}, journal={Clinical Lymphoma, Myeloma and Leukemia}, year=2022}